Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Non-pharmacologic strategies remain the foundation
Looking from 2023 to 2024, the latest year of data available, prescriptions and gross spending for Wegovy (first approved for obesity in 2021, approved for cardiovascular disease in 2024) and Mounjaro (approved for type 2 diabetes in 2022) more than doubled, and prescriptions and gross spending for Zepbound (first approved for obesity in 2023, approved for sleep apnea in 2024) increased more than fivefold
Waiting until hair starts falling out means the telogen shift already happened months ago
A better combination is CJC-1295 (either form) with Ipamorelin, a GHRP peptide that creates a complementary, synergistic GH release
Wegovy also showed a favorable safety profile
